Who makes Cholografin Meglumine?

Cholografin Meglumine is developed by Bracco.

What development phase is Cholografin Meglumine in?

Cholografin Meglumine is FDA-approved (marketed).

What is the generic name of Cholografin Meglumine?

adipiodone is the generic (nonproprietary) name of Cholografin Meglumine.

Last reviewed 2026-04-20 · How we verify

Cholografin Meglumine (adipiodone)

Bracco · FDA-approved active Quality 10/100

Adipiodone (Cholografin Meglumine), marketed by Bracco, is a contrast agent used in medical imaging to enhance visualization of certain tissues and structures. Its key strength lies in its ability to accumulate effectively in target areas, providing clear images essential for diagnostic procedures. The primary risk is the expiration of its key composition patent in 2028, which could lead to increased competition from generic alternatives.

At a glance

Generic name	adipiodone
Sponsor	Bracco
Drug class	Radiographic Contrast Agent
Therapeutic area	Gastroenterology
Phase	FDA-approved
First approval	1954

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

The Value of CT Cholangiography in Primary Sclerosing Cholangitis (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
FDA label	Mechanism, indications, dosing, boxed warnings, drug interactions
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Cholografin Meglumine CI brief — competitive landscape report
Cholografin Meglumine updates RSS · CI watch RSS
Bracco portfolio CI